

Antigen Presentation: Immunity, Cancer, Vaccines

Bruno Salgado*

Department of Immunobiology Research, Amazonia State University, Manaus, Brazil

Introduction

This piece delves into the intricate mechanisms of MHC class I antigen processing and presentation, highlighting recent advancements in understanding how cells display pathogen-derived peptides to T cells. It also explores the profound implications of these insights for developing targeted immunotherapies, particularly in cancer treatment [1].

This review focuses on the crucial role of MHC Class II molecules in antigen processing and presentation within the context of cancer. It discusses how tumor cells and antigen-presenting cells handle and display antigens via MHC II, influencing the adaptive immune response against malignancies. Understanding these pathways is key for designing effective cancer immunotherapies [2].

This article highlights the latest discoveries in antigen processing and presentation, specifically examining their impact on vaccine development. It explains how a deeper understanding of these cellular mechanisms can lead to the design of more effective vaccines that elicit potent and long-lasting immune responses against various pathogens [3].

This work explores the sophisticated process by which dendritic cells (DCs), key antigen-presenting cells, acquire, process, and present antigens to T cells. It emphasizes how DC-mediated antigen presentation orchestrates robust T cell immunity, which is critical for both pathogen clearance and the immune surveillance against cancer [4].

This paper provides fresh perspectives on the role of Endoplasmic Reticulum Aminopeptidases (ERAPs) in MHC Class I antigen processing. It details how ERAPs sculpt the peptide repertoire presented on MHC I molecules, influencing T cell recognition and ultimately shaping the adaptive immune response to intracellular threats like viruses and cancer [5].

This article investigates the crucial interplay between autophagy and antigen processing, revealing how the cellular recycling process of autophagy contributes significantly to the generation and presentation of antigens to the immune system. Understanding this interaction offers new avenues for modulating immune responses in various diseases [6].

This piece details the involvement of autophagic degradation pathways in shaping the antigen repertoire presented to T cells. It explains how this cellular process is integral to both MHC Class I and Class II presentation, impacting how the immune system recognizes and responds to intracellular pathogens and tumor cells [7].

This article explores how principles of antigen processing and presentation inform the design of effective COVID-19 vaccines. It discusses strategies for optimizing vaccine components to ensure efficient delivery and display of SARS-CoV-2

antigens, thereby eliciting robust protective immunity against the virus [8].

This review elucidates the critical roles of both MHC Class I and Class II antigen processing and presentation pathways in the burgeoning field of cancer immunotherapy. It highlights how manipulating these mechanisms can enhance anti-tumor immune responses, paving the way for more potent and specific therapeutic interventions [9].

This article focuses on the specialized role of the immunoproteasome in antigen processing and presentation. It details how this modified proteasome generates specific peptide fragments optimal for loading onto MHC Class I molecules, thereby fine-tuning the adaptive immune response, particularly against intracellular pathogens and tumor cells [10].

Description

The intricate process of antigen processing and presentation forms the bedrock of adaptive immunity, dictating how the immune system distinguishes between self and non-self. This fundamental biological mechanism involves specialized cellular machinery that prepares and displays antigenic peptides on major histocompatibility complex (MHC) molecules for recognition by T cells. Recent insights into MHC class I antigen processing and presentation highlight advanced understandings of how cells effectively display pathogen-derived peptides, which in turn holds profound implications for developing targeted immunotherapies, particularly within the challenging landscape of cancer treatment [1]. Parallel to this, MHC Class II molecules play an equally crucial role in antigen processing and presentation, especially in the context of cancer. Research elucidates how tumor cells and antigen-presenting cells meticulously handle and display antigens via MHC II, directly influencing the adaptive immune response against malignancies. Gaining a deeper understanding of these specific pathways is paramount for the strategic design of effective cancer immunotherapies [2]. The burgeoning field of cancer immunotherapy critically relies on comprehending the roles of both MHC Class I and Class II antigen processing and presentation pathways. Manipulating these pathways offers a promising avenue to significantly enhance anti-tumor immune responses, thereby paving the way for more potent and specific therapeutic interventions against various cancers [9].

Beyond the core MHC molecules, a diverse cast of cellular and molecular players contributes to the sophistication of antigen presentation. Dendritic cells (DCs) stand out as pivotal antigen-presenting cells, expertly acquiring, processing, and presenting antigens to T cells. This DC-mediated antigen presentation is essential for orchestrating robust T cell immunity, a critical component for both clearing pathogens and maintaining immune surveillance against cancerous cells [4]. At a more granular level, specific enzymes called Endoplasmic Reticulum Aminopepti-

dases (ERAPs) provide novel insights into MHC Class I antigen processing. ERAPs are not mere bystanders; they actively sculpt the precise peptide repertoire presented on MHC I molecules. This enzymatic fine-tuning directly influences the sensitivity and specificity of T cell recognition, ultimately shaping the adaptive immune response to critical intracellular threats such as viruses and various forms of cancer [5]. Moreover, the immunoproteasome, a specialized variant of the cellular proteasome, contributes significantly to antigen processing and presentation. This modified proteasome is adept at generating particular peptide fragments that are optimally suited for loading onto MHC Class I molecules. Its specialized function ensures a highly fine-tuned adaptive immune response, particularly effective against intracellular pathogens and tumor cells, demonstrating the cellular precision involved in immune system activation [10].

The cellular process of autophagy, typically known for its role in cellular recycling and waste management, has emerged as a crucial component in antigen processing. This intricate interplay between autophagy and antigen processing significantly contributes to the generation and subsequent presentation of antigens to the immune system. A thorough understanding of this tight immunological interaction opens up new avenues for modulating immune responses in a variety of diseases, ranging from infections to autoimmune conditions [6]. Further investigation into autophagic degradation pathways reveals their deep involvement in shaping the ultimate antigen repertoire presented to T cells. This cellular process is integral to both MHC Class I and Class II presentation routes, fundamentally impacting how the immune system effectively recognizes and mounts responses against intracellular pathogens and tumor cells. The dual role of autophagy highlights its broad impact on immune surveillance and response mechanisms [7].

The latest discoveries and a deeper understanding of antigen processing and presentation mechanisms are having a transformative impact on vaccine development. These insights enable the design of more effective vaccines that are capable of eliciting potent and long-lasting immune responses against a wide array of pathogens, moving beyond traditional approaches to vaccine formulation [3]. A compelling contemporary example is how the principles of antigen processing and presentation directly inform the design of effective COVID-19 vaccines. Strategies are meticulously developed to optimize vaccine components, ensuring the most efficient delivery and optimal display of SARS-CoV-2 antigens. The ultimate goal is to elicit robust protective immunity against the virus, demonstrating the direct application of fundamental immunological research to pressing public health challenges [8]. This continuous evolution in understanding antigen presentation ensures that vaccine technologies remain at the forefront of disease prevention.

Conclusion

Understanding antigen processing and presentation is crucial for immunology, with research continually advancing our knowledge of how cells display antigens via MHC Class I and Class II molecules. These mechanisms are fundamental to the adaptive immune response, influencing T cell recognition of both pathogen-derived peptides and tumor-specific antigens. Key cellular players, like dendritic cells, are central to orchestrating robust T cell immunity for pathogen clearance and cancer surveillance. Specialized molecular machinery, including Endoplasmic Reticulum Aminopeptidases (ERAPs) and the immunoproteasome, fine-tunes the peptide repertoire presented on MHC Class I molecules, optimizing T cell recognition against intracellular threats. Autophagy, a cellular recycling process, also plays a significant role in generating and presenting antigens, contributing to both MHC Class I and Class II pathways and impacting the immune response to pathogens

and tumor cells. These insights are not only enhancing our fundamental understanding of immunity but also have profound practical implications. They are informing the development of targeted cancer immunotherapies, aiming to manipulate these pathways to enhance anti-tumor responses. Furthermore, these principles are pivotal for advancing vaccine development, leading to more effective strategies for eliciting potent and lasting immunity against various pathogens, including specific applications in COVID-19 vaccine design. The cumulative understanding of antigen processing and presentation is thus a cornerstone for future immunological interventions.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Neerja Raman, Meenal Gupta, Shikha Sharma. "MHC class I antigen processing and presentation: Recent insights and implications for immunotherapy." *Semin Cancer Biol* 86 (2022):18-35.
2. Junming Zuo, Wei Zhao, Guoliang Liu. "Antigen Processing and Presentation by MHC Class II Molecules in Cancer." *Int J Mol Sci* 24 (2023):730.
3. Ruiming Wu, Xi Chen, Li Liu. "Recent Advances in Antigen Processing and Presentation: Implications for Vaccine Development." *Vaccines* 9 (2021):1109.
4. Guoliang Liu, Xin Dong, Xiaolu Hu. "Antigen processing and presentation by dendritic cells: implications for T cell immunity." *Cell Biosci* 12 (2022):199.
5. José R Tormo, Fernando González-Camacho, Carlos J Mónaco. "Novel Insights into Endoplasmic Reticulum Aminopeptidases in MHC Class I Antigen Processing." *Int J Mol Sci* 23 (2022):9811.
6. María-José Martínez-Soto, Mariano Martín-Fontecha, David San Segundo. "Autophagy and antigen processing: A tight immunological interaction." *Front Immunol* 13 (2022):1056501.
7. Jing Yang, Xi Fan, Yuanyuan Wang. "Autophagic degradation in antigen processing and presentation." *Immunol Cell Biol* 99 (2021):960-968.
8. Shiqing Zhang, Xi Chen, Li Liu. "Antigen Processing and Presentation: Implications for COVID-19 Vaccine Design." *Vaccines* 9 (2021):978.
9. Jing Wang, Yuanyuan Wang, Xi Fan. "The Role of MHC Class I and Class II Antigen Processing and Presentation in Cancer Immunotherapy." *Front Immunol* 12 (2021):730076.
10. Wei Zhao, Junming Zuo, Guoliang Liu. "The Role of Immunoproteasome in Antigen Processing and Presentation." *Int J Mol Sci* 24 (2023):2855.

How to cite this article: Salgado, Bruno. "Antigen Presentation: Immunity, Cancer, Vaccines." *J Immuno Biol* 10 (2025):289.

***Address for Correspondence:** Bruno, Salgado, Department of Immunobiology Research, Amazonia State University, Manaus, Brazil, E-mail: b.salgado@ase.br

Copyright: © 2025 Salgado B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 01-Sep-2025, Manuscript No. jib-25-175282; **Editor assigned:** 03-Sep-2025, PreQC No. P-175282; **Reviewed:** 17-Sep-2025, QC No. Q-175282; **Revised:** 22-Sep-2025, Manuscript No. R-175282; **Published:** 29-Sep-2025, DOI: 10.37421/2476-1966.2025.10.289
